Today we announced results from a large-scale Phase III trial, presented today in Durban, showing that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 months after vaccination.
Based on these data, next year we intend to submit a regulatory application to the European Medicines Agency (EMA). The World Health Organization has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible as early as 2015 if it is granted a positive scientific opinion by EMA.
We’re so excited to be a part of this team—11 African research centers in 7 African countries are conducting this trial, together with GSK and the PATH Malaria Vaccine Initiative (MVI), with whom we have a long partnership, with grant funding from the Bill & Melinda Gates Foundation to MVI.
And the response to the announcement has been encouraging throughout the day. Moncef Slaoui, head of R&D, has been talking to reporters all day—so I’m sure you’ll hear more on the news tonight!